1 / 43

Enhancing Gait Performance in Multiple Sclerosis Patients Using High-Contrast Visual Aids

This study explores the impact of deficient low-contrast sensitivity in patients with Multiple Sclerosis (M.S.) on gait performance and investigates the potential enhancements through high-contrast visual aids. The research assesses visual acuity, optic nerve thickness, and gait performance using specialized measurements and high-contrast lenses. Significant findings reveal the correlation between visual deficiencies and motor performance degradation in dim illumination conditions, with improvements observed with the use of yellow lenses for obstacle discrimination. The study emphasizes the importance of addressing contrast sensitivity deficits in M.S. patients to potentially reduce fall risks.

jmcmahon
Download Presentation

Enhancing Gait Performance in Multiple Sclerosis Patients Using High-Contrast Visual Aids

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Deficient Low-Contrast Visual Sensitivity Occurs in Patients with Multiple Sclerosis: May Degrade Gait Performance, Possible Modification Utilizing High Contrast Visual Aids. Rachel Tripoli Kelly Schwirian Dr. C.G. Maitland

  2. Background & Hypothesis • Balcer in 2000 (Balcer et al 2000) observed deficient low-contrast sensitivity in M.S. patients with and without optic neuropathy. • The impact of deficient low contrast sensitivity has not yet been explained in patients with M.S. to any degree. • Since optic neuropathy is found in over 80% of patients with M.S., it seems prudent to investigate any mechanism that might improve the function of affected individuals. • The application of high-contrast, blue-blocking yellow lenses was investigated in hopes of improving vision in low-contrast environments, and thus possibly allowing for better obstacle discrimination.

  3. Methodology • Four parameters were used to stage the degree of pathology of patients with multiple sclerosis and age matched controls • Estimated Disability Severity Scale • Ten-point scoring system that evaluates visual, motor, brainstem, sensory, and cognitive dimensions of patients with M.S. • Low Contrast Sloan Letter Chart • Optical Coherence Tomography • Gait Pad Measurement

  4. Methodology Patients tested with both eyes first, then right and left eye individually first at 100% efficiency, then at 2.5%, and then at 1.25% efficiency. The Snellen visual acuity equivalent will be determined by the lowest line read on the 100% chart. Low Contrast Sloan Chart

  5. Methodology To ensure a complete assessment of optic nerve topography, patients were examined using optical coherence tomography to assess thickness of the optic nerve fiber bundle. Optic Coherence Tomography

  6. Methodology Patients were asked to walk on a 22 foot gait pad that measures 102 parameters of gait The GaitRitepad (CIR Systems, Inc.) contains six sensor pads that extract readings from over 16,000 sensors embedded within a carpet that record patient data in an area 24 inches wide and 1400 inches long. Ambulation time, velocity, right and left footfall pressure and duration, and Functional Ambulation Performance (FAP) scores were calculated for each patient. GaitRite Pad Measurement http://www.gaitrite.com/Products/index-new.html

  7. Methodology Our study consisted of 22 MS patients and 22 age-matched controls • EDSS Assessment • Evaluated on a scale of 0 – 10 based on disease progression • Visual Acuity • Measured using the Sloan chart at 100%, 2.5%, and 1.25% • Contrast vision measured with both eyes, the right eye, and the left eye • OCT • Used to measure optic nerve thickness

  8. Methodology • GaitRite Pad 8 randomized walking trials per patient • 4 in high illumination (> 80 candela) • 2 with obstacles • 1 with lenses and 1 without • 2 without obstacles • 1 with lenses and 1 without • 4 in dim illumination (< 4 candela) • 2 with obstacles • 1 with lenses and 1 without • 2 without obstacles • 1 with lenses and 1 without • MEASUREMENTS • Functional ambulation profile (FAP) • Step number, normalized velocity, step length, step length differential, stride length, and cadence

  9. Significant Findings *Evaluated using paired T-testing • Poorer contrast visual acuity in MS patients • Measured using the Sloan chart • Significant difference at 100%, 2.5%, and 1.25% • MS patients had thinner optic nerves • Measured using OCT • Thinner optic nerves correlated negatively with visual acuity • Patients with thinner optic nerves (measured using OCT) had poorer performance on the Sloan chart

  10. Significant Findings • Visual deficiency significantly degraded motor performance in dim illumination • Especially seen with complicated walking (obstacles) • Significant differences seen in FAP, velocity, normalized velocity, cadence, step length, and stride length • No deficiency seen in high illumination • Negative correlation between FAP and EDSS scores • MS patients with an EDSS score of 4 or less had significantly worse FAP scores than those with a score of 4 or greater • Yellow lenses improved FAP scores of MS patients in dim illumination • Especially significant with complicated walking (obstacles) • No significant differences seen between MS patients and controls in dim illumination with lenses

  11. Conclusion • Contrast sensitivity deficits degrade motor performance in MS patients in dim illumination • These deficits are presumably the result of optic neuropathy • MS patients have decreased FAP scores • Low FAP scores correlate highly with increased fall risk • High-contrast yellow lenses improve low-contrast vision in MS patients • These lenses increase obstacle discrimination, and could potentially result in a reduction in risk of injury from falls

  12. References Balcer LJ , Baier ML , Pelak VS , et al. (2000). New low-contrast vision charts (reliability and test characteristics in patients with multiple sclerosis). MultScler. 6,163–171 Frohman, E. M., Fujimoto, J. G., Frohman, T. C., Calabresi, P. A., Cutter, G., & Balcer, L. J. (2008). Optical coherence tomography: a window into the mechanisms of multiple sclerosis. [10.1038/ncpneuro0950]. Nat ClinPract Neuro, 4(12), 664-675. FUNDING FOR THIS RESEARCH PROVIDED BY: FSU College of Medicine TMH Foundation

  13. Contrast sensitivity • Definition: Spacial contrast. • A physical dimension referring to the light dark transition at a border or an edge of an image that delineates the existence of a pattern or object.

  14. Spacial Contrast • Contrast is expressed as a percentage from 0 to 100%. When contrast is 0% there is no edge between the two adjacent areas ie no pattern is physically present.

  15. Spacial Contrast • For any value greater than 0%, an edge exists even though it may or may not be visible, depending on the image processing capabilities of the detector.

  16. Contrast Sensitivity • The amount of contrast a person needs to see a target is called contrast threshold . In clinical research, it is expressed as contrast senstivity which is simply the reciprocal of threshold.

  17. Visual Testing by SLOAN charts • Measure of visual acuity through standardized charts descending in contrast sensitivity • Begins with 100% contrast to measure directive visual acuity • 2.5% and 1.25% contrast used as a measure of low contrast sensitivity

  18. Why Bother ? • CS may uncover a hidden dysfunction not apparent by other visual evaluations. • Optic neuritis • Cerebral lesions • Age related cataract

  19. Why Bother? • Provides another visual parameter to monitor the impact of treatment • interventions. • MS platform and novel • therapies. • Rasagaline

  20. Why Bother? • Provides insights into the extent of functional performance problems. • Difficulties: mobility • driving • reading • using tools

  21. Parkinson’s and contrast sensitivity What are the clinical implications of deficit in contrast sensitivity visual acuity in Parkinson’s disease?

  22. Parkinson’s and CSVA History • BodisWolner (1987): Loss of spaciotemporal contrast sensitivity • Frederick (1982): Dopaminergicamacrine neurons in human retina • Harnois: (1990): Decreased dopamine/metabolites in retina in Parkinsonism • Ikeda (1994): Electroretinographic evidence of retinal dopamine deficiency • Ghilardi (1988): Pattern ERG same in idiopathic PD and monkey model • Inzelberg (2004): OCT and retinal NFB thinning • Hajee (2009): Inner retinal layer thinning ( Optovue )

  23. History of PD Contrast Sensitivity • Contrast sensitivity is deficient in Parkinson’s • Can be identified with CS wall charts (Sheriff et al –NANOS 2009) • Limited functional studies of effects on motor performance: • Rizzo (2009):Driving under low-contrast visibility conditions • Owsley (1987):The perception of “real world” targets • Moes (2009):Contrast sensitivity, gait and reading speed

  24. Hypotheses • Compared with controls, patients will exhibit a deficiency in contrast sensitivity as measured with simple wall charts (SLOAN) • Patients walking performance will degrade significantly in low contrast conditions compared to controls • There will be a correlation between poorer performance on the SLOAN and walking performance in dim illumination.

  25. Parkinsonism • 31 Male • 20 Female • 8 Male • 22 Female Demographics: -51 Patients -30 Controls -Mean Age: 70 -Mean Age: 65 -Mean UPDRS: 24 ***All on some dopaminergic medication; no anticholinergics with exception of Amantadine Exclusions: -Inability to walk independently Canes and walkers allowed -Known treated glaucoma or macular disease -VA < 20/50 -Significant comorbid cardiovascular or neurologic disease -Dementia (MOCA)

  26. Methodology • A general neurologic examination including standardized scoring for Parkinson’s severity (UPDRS) • Directive and contrast visual acuity tests utilizing SLOAN wall charts at 80 candela at 100%, 2.5%, 1.25% efficiency • Participants walked 18 feet on a gait pad measuring 102 parameters of gait (GAITRite) in randomized conditions of high and dim illumination.

  27. Parkinson’s UPDRS II. ACTIVITIES OF DAILY LIVING (for both "on" and "off") 8. Handwriting 0 = Normal. 1 = Slightly slow or small. 2 = Moderately slow or small; all words are legible. 3 = Severely affected; not all words are legible. 4 = The majority of words are not legible. 9. Cutting food and handling utensils 0 = Normal. 1 = Somewhat slow and clumsy, but no help needed. 2 = Can cut most foods, although clumsy and slow; some help needed. 3 = Food must be cut by someone, but can still feed slowly. 4 = Needs to be fed. 10. Dressing 0 = Normal. 1 = Somewhat slow, but no help needed. 2 = Occasional assistance with buttoning, getting arms in sleeves. 3 = Considerable help required, but can do some things alone. 4 = Helpless. 11. Hygiene 0 = Normal. 1 = Somewhat slow, but no help needed. 2 = Needs help to shower or bathe; or very slow in hygienic care. 3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom. 4 = Foley catheter or other mechanical aids. III. MOTOR EXAMINATION 22. Rigidity (Judged on passive movement of major joints with patient relaxed in sitting position. Cogwheeling to be ignored.) 0 = Absent. 1 = Slight or detectable only when activated by mirror or other movements. 2 = Mild to moderate. 3 = Marked, but full range of motion easily achieved. 4 = Severe, range of motion achieved with difficulty. 23. Finger Taps (Patient taps thumb with index finger in rapid succession.) 0 = Normal. 1 = Mild slowing and/or reduction in amplitude. 2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement. 4 = Can barely perform the task. 24. Hand Movements (Patient opens and closes hands in rapid succesion.) 0 = Normal. 1 = Mild slowing and/or reduction in amplitude. 2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement. 4 = Can barely perform the task.

  28. Parkinson’s Gait Functional Ambulation Performance (FAP) • Scoring system that integrates selected time and distance parameters to provide a single, numerical representation of gait • Consists of a linear relationship of step length/ leg length ratio to step time when velocity is normalized to leg length

  29. GAITRITE SYSTEM • Measure the overall Functional Ambulatory Score (FAP) and its main parameters • Cadence • Velocity • Step Length • Step Time

  30. SLOAN Contrast Sensitivity Comparison

  31. Parkinson’s 100% SLOAN

  32. Parkinson’s 2.5% SLOAN

  33. Parkinson’s 1.25% SLOAN

  34. Parkinson’s Gait Data P=2.35E-09

  35. Parkinson’s Gait Results • Confirms contrast sensitivity defects • Motor performance degrades in dim illumination even in early stages of Parkinsonism • Deficient contrast sensitivity heightens fall risk likely due to retinal dopamine deficiency

  36. Parkinson’s and CS • The clinical significance of a degraded FAP score rests in well documented correlations between FAP and fall risk. • Parkinson’s patients fall at start and when cadence is interrupted. • Contrast sensitivity disrupts cadence.

  37. Parkinson’s Gait Results • Plausible correlation between CS and FAP • No correlation between CS and age • No correlation between UPDRS and CS • Might reflect discrepancy between part II and III of UPDRS • Might reflect drug affect (peak/trough)

  38. Two Questions • What about yellow lenses? • 39 patients vs 30 age matched controls • How early does CS deficiency develop in parkinsonism? • No statistical significance between control data • Patient significance: p-value = 0.04

More Related